Skip to main content
. Author manuscript; available in PMC: 2018 Jan 18.
Published in final edited form as: Sci Transl Med. 2017 Jan 18;9(373):eaai8030. doi: 10.1126/scitranslmed.aai8030

Fig. 1. The collagen IV–derived mimetic peptide AXT107 causes suppression and regression of choroidal NV.

Fig. 1

(A) C57BL/6 mice had laser-induced rupture of Bruch’s membrane at three locations in one eye followed by an intraocular injection of 0.1 or 1 μg of AXT107, 1 μg of scrambled control peptide, or 40 μg of aflibercept. After 14 days, mice were euthanized, and retinas were dissected, stained with Griffonia simplicifolia lectin (GSA), and flat-mounted. (B) Eyes injected with 1 μg of AXT107 and 40 μg of aflibercept had significantly greater reduction in area of choroidal NV than either alone. (C) C57BL/6 mice (n = 43) had laser-induced rupture of Bruch’s membrane at three locations in one eye, and after 7 days, 12 mice were euthanized and the baseline mean area of choroidal NV was measured. The remaining mice received an injection of 0.1 or 1 μg of AXT107 or 1 μg of control peptide, and 7 days after injection, the mice were euthanized and the area of choroidal NV was measured. C, control; A, aflibercept; BL, baseline. Bars represent mean (± SEM). ***P < 0.001 for difference from control, **P < 0.01 for difference from baseline, †P < 0.05 for difference from AXT107 or aflibercept by analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons.